Immunotherapy as a promising treatment strategy for dMMR colorectal cancer with brain metastasis: a case report

Abstract

Brain metastasis in colorectal cancer is a rare occurrence with poor prognosis and limited treatment options. This case report presents a unique and previously unreported case of brain metastasis in a patient with dMMR (DNA mismatch repair-deficient) colorectal cancer. The patient, a 70-year-old male, initially presented with abdominal pain and was diagnosed with moderately differentiated adenocarcinoma of the right colon. Following surgical resection and adjuvant chemotherapy, the patient developed cognitive decline and was found to have a metastatic lesion in the left temporal lobe. Immunohistochemical analysis revealed MSH2 positivity and MSH6, MLH1, and PMS2 negativity, indicating dMMR status. Further genetic testing showed wild-type Kras, Nras, and Braf, and high tumor mutational burden (TMB). The patient was subsequently treated with pembrolizumab immunotherapy, resulting in a significant improvement of symptoms and a reduction in the size of brain metastasis. This case highlights the rarity and challenging management of brain metastasis in colorectal cancer, particularly in the context of dMMR tumors. The successful use of immunotherapy in this case provides valuable insights into the potential efficacy of immune-based treatments for dMMR colorectal cancer with brain metastasis, underscoring the need for further research in this field.

Keywords

Brain metastasis / colorectal cancer (CRC) / dMMR/MSI-H / immunotherapy

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Biller LH.Diagnosis and treatment of metastatic colorectal cancer: a review.JAMA2021;325:669-85

[3] Mjahed RB,Roth A.Where are we now and where might we be headed in understanding and managing brain metastases in colorectal cancer patients?.Curr Treat Options Oncol2022;23:980-1000 PMCID:PMC9174111

[4] Taieb J,Cohen R,Tougeron D.Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment.Eur J Cancer2022;175:136-57

[5] Le DT,Wang H.PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med2015;372:2509-20

[6] Chen KH,Tseng LH,Yeh KH.Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.J Hematol Oncol2016;9:29 PMCID:PMC4806434

[7] Overman MJ,Wong KYM.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.J Clin Oncol2018;36:773-9

[8] André T,Wong KYM.Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from checkmate 142.Ann Oncol2022;33:1052-60

[9] Diaz LA Jr,Kim TW.KEYNOTE-177 InvestigatorsPembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.Lancet Oncol2022;23:659-70 PMCID:PMC9533375

[10] Ward R,Tomlinson I,Norrie M,Hawkins N.Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.Gut2001;48:821-9 PMCID:PMC1728324

[11] Middha S,Nafa K.Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data.JCO Precis Oncol2017;1:1-17 PMCID:PMC6130812

[12] Adeleke S,Choy A.Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls.Per Med2022;19:277-86

[13] Cohen PR.Germline testing of mismatch repair genes is needed in the initial evaluation of patients with Muir-torre syndrome-associated cutaneous sebaceous neoplasms: a case series.Cureus2023;15:e33975 PMCID:PMC9941027

[14] Silva JR,Neto do Nascimento C.Role of endoscopic biopsies and morphologic features in predicting microsatellite instability status in gastric cancer: a multicenter comparative study of endoscopic biopsies and surgical specimens.Am J Surg Pathol2023;47:990-1000

[15] Cheng X,Chen D,Liu F.Primary tumor resection provides survival benefits for patients with synchronous brain metastases from colorectal cancer.Diagnostics2022;12:1586 PMCID:PMC9322496

[16] Müller S,Hendricks A.Brain Metastases from colorectal cancer: a systematic review of the literature and meta-analysis to establish a guideline for daily treatment.Cancers2021;13:900 PMCID:PMC7924831

[17] Suh JH,Chao ST,Sahgal A.Current approaches to the management of brain metastases.Nat Rev Clin Oncol2020;17:279-99

[18] Arvanitis CD,Jain RK.The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.Nat Rev Cancer2020;20:26-41 PMCID:PMC8246629

[19] André T,Kim TW.KEYNOTE-177 InvestigatorsPembrolizumab in microsatellite-instability-high advanced colorectal cancer.N Engl J Med2020;383:2207-18

[20] Marabelle A,Ascierto PA.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol2020;38:1-10

[21] Jardim DL,de Melo Gagliato D.The challenges of tumor mutational burden as an immunotherapy biomarker.Cancer Cell2021;39:154-73 PMCID:PMC7878292

[22] Sha D,Budczies J,Stenzinger A.Tumor mutational burden as a predictive biomarker in solid tumors.Cancer Discov2020;10:1808-25 PMCID:PMC7710563

[23] Shimozaki K,Hirota T.Current strategy to treat immunogenic gastrointestinal cancers: perspectives for a new era.Cells2023;12:1049 PMCID:PMC10093684

[24] Ott PA,Berton-rigaud D.Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study.JCO2017;35:2535-41

[25] Bortolomeazzi M,Montorsi L.Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts.Gastroenterology2021;161:1179-93 PMCID:PMC8527923

[26] Andre T,Norquist JM.Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.Lancet Oncol2021;22:665-77

[27] Hu H,Zhang J.Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.Lancet Gastroenterol Hepatol2022;7:38-48

[28] Liu DX,He W.PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.Oncoimmunology2020;9:1711650 PMCID:PMC6984585

[29] Ganesh K,Cercek A.Immunotherapy in colorectal cancer: rationale, challenges and potential.Nat Rev Gastroenterol Hepatol2019;16:361-75 PMCID:PMC7295073

[30] Duan X,Zhang Y,Zhou J.DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18.Cancer Sci2022;113:3672-85 PMCID:PMC9633303

[31] Dobbin KK,Alvarez J.Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.J Immunother Cancer2016;4:77 PMCID:PMC5109653

[32] Smith C,Dong J.Tumor microenvironment in pancreatic ductal adenocarcinoma: implications in immunotherapy.World J Gastroenterol2022;28:3297-313 PMCID:PMC9346457